7 results
8-K
RCUS
Arcus Biosciences Inc
5 Jun 23
Regulation FD Disclosure
8:25am
+
zimberelimab (“EDZ”) (n=50)
Progression-free Survival (PFS)
Median in Months (95% CI)
5.4 (2.7, 9.7)
9.3 (4.1, NE)
9.9 (4.8, 14.6)
Hazard Ratio* (95% CI
8-K
RCUS
Arcus Biosciences Inc
19 Dec 22
Other Events
5:05pm
(PFS)
Median in Months (95% CI)
12.0 (5.5, NE)
10.9 (4.8, NE)
Hazard Ratio* (95% CI)
Six-month PFS rate (95% CI)
Objective Response Rate (ORR)
ORR … + (95% CI)
*Hazard ratio is for comparing domvanalimab-containing study arms to zimberelimab monotherapy.
+Based on confirmed response per RECIST 1.1
10-K
qox7w1d1u0
5 Mar 19
Annual report
12:00am
- Prev
- 1
- Next